Cancer Genetics and Epigenetics 2024, Vol.12, No.6, 306-316 http://medscipublisher.com/index.php/cge 316 Uhlik M., Bose N., Cox J., Mattson P., Gargano M., o'Day S., Borges V., Chmielowski B., Rao R., Abu-Khalaf M., Stopeck A., Chisamore M., Osterwalder B., and Graff J., 2020, Abstract PD1-02: Response and clinical benefit assessment of the combination of the dectin-1 agonist imprime PGG and anti-PD-1 pembrolizumab in chemotherapy-resistant metastatic triple negative breast cancer (TNBC), Cancer Research, 80(4_Supplement): PD1-02.. https://doi.org/10.1158/1538-7445.sabcs19-pd1-02 Varma R., Wright M., Abraham J., and Kruse M., 2022, Immune checkpoint inhibition in early-stage triple-negative breast cancer, Expert Review of Anticancer Therapy, 22(11): 1225-1238. https://doi.org/10.1080/14737140.2022.2139240 PMID: 36278877 Wu Q., Wu C.L., and Xie X.H., 2022, Efficacy and safety of immune checkpoint inhibitors in triple-negative breast cancer: a study based on 41 cohorts incorporating 6558 participants, Journal of Immunotherapy, 46(2): 29-42. https://doi.org/10.1097/CJI.0000000000000447 PMID: 36378154 Yi H.M., Li Y., Tan Y., Fu S.J., Tang F.Q., and Deng X.Y., 2021, Immune checkpoint inhibition for triple-negative breast cancer: current landscape and future perspectives, Frontiers in Oncology, 11: 648139. https://doi.org/10.3389/fonc.2021.648139 PMID: 34094935 PMCID: PMC8170306 Yuan X., Xiao Y., Liu X., Kuo W., Li H.Z., Li P., Yagita H., and Yu D., 2018, Abstract 4565: effective inhibition of metastasis in triple-negative breast cancer (TNBC) mouse model by combining immunogenic chemotherapy and immune checkpoint blockade, Clinical Research (Excluding Clinical Trials), 78(13_Supplement): 4565. https://doi.org/10.1158/1538-7445.Am2018-4565 Zhang Y.Y., Chen H.Y., Mo H.N., Hu X.D., Gao R.R., Zhao Y.H., Liu B.L., Niu L.J., Sun X.Y., Yu X., Wang Y., Chang Q., Gong T.Y., Guan X.W., Hu T., Qian T.Y., Xu B.H., Ma F., Zhang Z.M., and Liu Z.H., 2021, Single-cell analyses reveal key immune cell subsets associated with response to PD-l1 blockade in triple-negative breast cancer, Cancer Cell, 39(12):1578-1593. https://doi.org/10.1016/j.ccell.2021.09.010 PMID: 34653365 Zhao W.H., Zhang Z., Zhang Y.D., Chen Y.M., Zhu Y.M., Liu C.L., Shao J.K., Zhang L., and Liu M., 2023, A real-world study of immune checkpoint inhibitors in advanced triple-negative breast cancer, Journal of Clinical Oncology, 2(3): 172-180. https://doi.org/10.1200/jco.2023.41.16_suppl.e13090
RkJQdWJsaXNoZXIy MjQ4ODYzNQ==